Mediscience Tecnology Corp.
Home   About   Investor Relations   News   Intellectual Property   Products   Alliances
  News Releases
 

Current

 
 

Archives

 

April 03, 2006: FDA Approves Mediscience Optical Biopsy Device Multi-Center Pilot Study for Molecular Cancer Detection of the Cervix

March 07, 2006: Mediscience and Alfanix Technology in Alliance to Build and Test Sophisticated Photonics Cancer Diagnostics Devices

January 05, 2006: Mediscience Inc. Files Investigational Device Exemption (IDE) Application with the Center for Devices and Radiological Health of the FDA

November 28, 2005: Mediscience Technology Corp. Announces Board Additions

November 10, 2005: Mediscience Technology Corp. Names Frank Benick, CPA Chief Financial Officer

October 26, 2005: Mediscience Technology Corp. and Infotonics Technology Center Inc. Report "Compact Photonic Explorer" (CPE), "Pill Camera" Progress

September 6, 2005: Mediscience Technology Engages Investment Bankers

Aug 17, 2005: Mediscience Technology Corp. Announces Its Successful Closing on August 16, 2005 of a $1.525 Million Dollar Private Placement

July 26, 2005: Mediscience Technology Corp. Sets Meeting Date with FDA to Review Pre-IDE Submission Regarding Cancer Detection Device; Mediscience to Meet with FDA on August 18, 2005 to Discuss Its CD-Ratiometer Dev

May 12, 2005: Mediscience Technology Corp. Announces Pre-IDE Meeting Request for CD-Ratiometer, a Cancer Detection Device

April 11, 2005: Mediscience Technology Corp. Developing Cancer Detection Instrument for Analyzing Surgical Breast Tissue Specimens at Point-of-Care

January 27, 2005: Mediscience Technology Corp. Names Dr. Julian Kim as consultant for the development of the jointly proposed micro-endoscopic device utilizing MTC proprietary technology for native fluorescence molecular measurements of breast ducts

December 9, 2004: Mediscience Technology Corp. Announces Completion of Development of Its Optical Biopsy Cancer Diagnostic Ratiometer and Submission to the FDA of the Pre-IDE Briefing Materials

November 11, 2004: Mediscience Technology Corp./Medi-photonics Development Company LLC and Infotonics Technology Center Announce Their Definitive Collaborative R&D Equity Agreement

September 8, 2004: Infotonics Technology Center and Medi-photonics Development Company LLC announced their intent to agree to jointly develop the "Compact Photonic Explorer". Infotonics is a consortium that includes Corning, Inc., Eastman Kodak Company, and Xerox Corporation, and several New York State universities. Infotonics is a world-class research and development facility established to enable the rapid commercialization of new high tech products.

August 2, 2004: Mediscience Technology Corp. Prevents Unauthorized Listing of Company Stock on Berlin-Bremen Stock Exchange

June 15, 2004: New CD-ROM from Optical Society of America offers comprehensive collection of papers on biomedical optical biopsy. To order the CD-ROM Biomedical Optical Biopsy from the Optical Society of America please go to www.osa.org/pubs/bookstore2

May 2, 2004: Mediscience Technology Corp. (otc-mdsc) Announces Project Agreement For Development Of Cancer Detection And Diagnosis Device With Research Foundation Of The City University Of New York

April 14, 2004: Mediscience Technology Corp. (otc-mdsc) Names Robert G. Pinco to Advisory Council

Feb 2, 2004: Mediscience Technology Corp. (otc-mdsc) announces the successful closing of a $1.5 Million dollars Private Placement as of February 1, 2004


FDA APPROVES MEDISCIENCE OPTICAL BIOPSY DEVICE MULTI-CENTER PILOT STUDY FOR MOLECULAR CANCER DETECTION OF THE CERVIX

CHERRY HILL, N.J., Apr 03, 2006 -- Mediscience Technology, Corp. (OTCBB:MDSC.OB) announced today: The Food and Drug Administration on March 29, 2006 approved as a "Non-significant risk device study the Company's multi-center pilot study to establish the safety and parameters of efficacy of its proprietary Optical Biopsy Device (CD-R) for cancer detection of the cervix preliminary to a pivotal study" expected to bring this molecular algorithmic specific technology to market.

Dr Robert Schiff of Schiff & Company/ Regulatory Affairs advised "The FDA has notified Mediscience that the device (CD-R) is a non-significant risk device. We can therefore commence the Pilot study at any time observing the regulations governing patient consent and institutional IRB approval. The FDA has also given us comments and suggestions which will assist Mediscience in its clinical studies."

Peter Katevatis Chairman/CEO: "The main objectives of this pilot study are to determine efficacy; the clinical sensitivity and clinical specificity (ability for the device to distinguish between tissues that are normal, benign, precancerous low grade, precancerous high grade, CIS and cancer) by comparing the device real-time results to the PAP test and biopsy; and assess any adverse events based on Good Clinical Practices. Frequency, type and intensity of clinical adverse events will also be evaluated. Assuming the results of this initial efficacy and safety study are satisfactory, in the detection of cervical cancer precursors i.e. (pre-cancerous cells), indications of possible cancer development the Company will continue into its pivotal study where the principal endpoint will be proof of effectiveness in a statistically significant sample of subjects."

Dr. Robert Alfano (pioneer in optical biopsy, co-founder and advisor to Mediscience Technology and President of Alfanix LTD): "This FDA approval advances Mediscience to the next level towards commercialization and is a major step in advancing diagnostic medicine using fluorescence light. Alfanix plans to help Mediscience with its CD-R platform technology in the medical cancer areas and possibly expanding the market into Latin America."

Mediscience Technology Corporation is engaged in the design and development of fluorescence-based optical biopsy platform system that uses the properties of light and its molecular interaction with tissue to aid in the diagnosis of physiological change and cancer. The Mediscience IP technology platform is based on imaging native fluorescence from the surface of an optically excited tissue and offers paradigm shift potential as a noninvasive, in-vivo cancer diagnostic because of the unique ability to detect/distinguish abnormalities in molecular tissue composition and/or structure. Further, the development of a Mediscience cost effective, high resolution commercial imaging system for real-time in-vivo diagnostics has the potential to vastly improve upon current standards of diagnostic sensitivity and specificity. (e.g. Cervical cancer a highly preventable cancer with early detection and removal of pre-cancerous cervical lesions)

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, pre-cancerous or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

medisciencetech.com

Mediscience 8-K filing dated April 4, 2006

New England Journal of Medicine 7-29-04 (capsule endoscopic technology)

CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page 20 (Mediscience/Infotonics)

Alfanix LTD Dr Robert Alfano 917 969 2209 [email protected]

Top of page

MEDISCIENCE AND ALFANIX TECHNOLOGY IN ALLIANCE TO BUILD AND TEST SOPHISTICATED PHOTONICS CANCER DIAGNOSTICS DEVICES

CHERRY HILL, N. J.--March 7, 2006-- Mediscience Technology Corp. (OTCBB:MDSC) (Mediscience) and Alfanix Technology, Ltd. (ATL) are pleased to announce an alliance to construct sophisticated photonics devices for cancer diagnostics, such as the Cancer Diagnostic Ratiometer (CD-R); and to introduce the devices into Latin America for testing on human subjects. CD-Rs use light fluorescence to distinguish between cancerous and non-cancerous tissues to obtain a more accurate in situ optical PAP test. CD-R results are immediate, whereas diagnosis via conventional PAP smears takes approximately one week. While CD-Rs are seen as a supplement for conventional PAP smears initially, they may eventually serve as a substitute. The alliance was announced jointly by Mr. Peter Katevatis Esq., Chairman and CEO of Mediscience, and Dr. Robert R. Alfano, President and CEO of ATL. The alliance will be funded by Mediscience, a public company trading on the OTC Bulletin Board under the symbol "MDSC."

As part of the alliance, ATL will oversee the construction for Mediscience of CD-R Beta units for use in clinical testing. At least two will be used for clinical tests in the Dominican Republic under the supervision of ATL; and at least two will be used for similar trials in the United States under the supervision of Mediscience. The objective is to obtain algorithms in order to evaluate and improve the efficacy of CD-Rs on human subjects. With a high index rate of GYN cancer among Latin America's female population, there is an urgent need for a more accurate approach to detect and diagnose the disease. The ability to diagnose cancer in real time, offers the added benefit of being able to provide life-saving treatment for cervical cancer that otherwise might not be available because of the difficulty of getting many Latin American women to return for treatment after providing them with a delayed diagnosis of malignancy based on the examination of a PAP smear.

ATL is a New York State for-profit company focusing on developing, building and selling photonics-based medical and non-medical devices, Cr laser crystals, novel compact lasers, and photonics related technology. ATL's mission is to help companies develop and market photonics products; and assist with testing and marketing of these products in the United States and internationally with an emphasis on Latin America. ATL is developing a network of doctors and hospitals in Latin America, starting with the Dominican Republic, for the introduction, testing, and marketing of photonics-based medical products for detection and diagnosis of cancer of the GYN tract, breast, and skin. In return for developing and introducing a marketable product for companies under contract, ATL will receive an agreed upon royalty and/or a percentage interest in either the product-line or the company. The alliance between ATL and Mediscience includes the identification of and subsequent training of medical teams in the Dominican Republic to use the CD-R system. Medical teams will be composed of an oncologist, pathologist and medical technician.

Dr. Alfano stated that, "this Agreement will enhance the development of the CD-R and other sophisticated photonics devices that have the potential to become important new cancer diagnostic tools. It will also help to bring Mediscience to the next level in marketing cancer fluorescence devices." Mr. Katevatis added, " this extraordinary Alliance contractually endows Mediscience with on-going technical resources, not available in any other single individual or un- experienced entity, to be applied to our CD-R, technology, our FDA clinicals and subsequent sequential market entry of additional Mediscience Platform applications."

Dr. Alfano is the inventor of fluorescence technology and the developer of the CD-R. He noted that the Latin American and Dominican Republic connections regarding the CD-R and other Photonics products will also bring high technology and valuable training to those regions in a number of fields, including tunable lasers, laser crystals technology, and water pollution detection based on the fluorescence of bacteria.

Mediscience and ATL are clients of CUNY's New York State Center for Advanced Technology in Photonics Applications. The CUNY-CAT develops and disseminates knowledge in photonics technology in order to promote New York State economic development for the medical, biological, industrial and military sectors; and provides New York State companies with research services, including infrastructure and business development.

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its herein indicated present CD-R and long-range business plan for various other applications of its technology; the company's ability to enter into successful agreements with any necessary or desirable marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US or Latin American Country regulatory or other approvals/ clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

This disclosure is intended to satisfy: SEC Section 6,6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Ref: 8-K filing dated March 6, 2006

medisciencetech.com

CONTACT: Mediscience Technology Corp.
Peter Katevatis Esq., 215-485-0362
[email protected]
or
Alfanix
Dr. Robert Alfano, 917-969-2209
www.Alfanix.com

Top of page

MEDISCIENCE INC. FILES INVESTIGATIONAL DEVICE EXEMPTION (IDE) APPLICATION WITH THE CENTER FOR DEVICES AND RADIOLOGICAL HEALTH OF THE FDA

CHERRY HILL, N.J., Jan 05, 2006 -- MEDISCIENCE TECHNOLOGY CORP. -- Mediscience (MTC) (OTCBB:MDSC) reported that it has filed an Investigational Device Exemption (IDE) application with the Center for Devices and Radiological Health of the FDA. The filing is subject to evaluation by the FDA to determine when a proposed human clinical pilot study of the Company's Cervical Cancer Detection Radiometer (CD-R) may begin.

Mediscience Chairman Peter Katevatis Esq. stated, "This anticipated pilot study for the initiation of MTC adjunct clinical trials brings the Company one step closer to commercialization of its broad patented Optical Biopsy technology platform applications. We further believe that any and all acquired FDA/MTC approvals will add significant synergistic and applicable value to our Joint effort with INFOTONICS RESEARCH CORP. in the development of the 'Compact Photonic Explorer' (CPE), or 'pill camera,' an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract with our embedded patented Optical Biopsy technology platform."

The clinical objectives are to demonstrate the device's ability to distinguish between tissues that are normal, benign, precancerous low grade, precancerous high grade, and cancerous. The device results will be compared to the PAP test and tissue biopsy and will be evaluated for clinical adverse events.

The pilot study will enroll 400 patients in a multi-center study of sensitivity and specificity of MDSC's precancer/cancer detection ratiometer (CDR) device. Two groups of 50-75 patients each will be tested to define the spectral characteristics of the normal and cancerous cervix (histology). The remaining population will be tested to define intermediary states between normal and various stages of cancer.

Mediscience and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that aid in the molecular diagnosis of cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. The Company's exclusive protected IP non-invasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection and offers a paradigm shift unique ability to detect molecular abnormalities in tissue composition and/or structure with out patient health hazard.

The Infotonics Technology Center Inc. (Infotonics) operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue. Infotonics is a present and significant shareholder of MTC.

See Web sites:

www.cunyphotonics.com

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

medisciencetech.com

See Mediscience 8-K filing dated Sept 8 2005 (MTC and INFOTONICS to jointly develop the "Compact Photonic Explorer" (CPE), or "pill camera")

See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology)

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, FDA approvals, the availability of financing, the parties/company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances, including but not limited to FDA, applicable to various applications/submissions of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SOURCE: Mediscience Technology Corp.

Mediscience Technology Corp. Michael Engelhart, 201-818-0050 [email protected] or Peter Katevatis Esq. 215-485-0362 [email protected] or Infotonics Technology Center Inc. David Smith, 585-919-3000 [email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES BOARD ADDITIONS

CHERRY HILL, N.J., Nov 10, 2005 -- Mediscience Technology Corp. (OTCBB:MDSC) announced, effect immediately, Joseph Franchetti, Dr. Anil Rastogi and Sidney Braginsky have joined the Mediscience Board as independent directors (see 8-K filing November 28, 2005 for complete and specific detailed CV's of the three.

Joseph Franchetti: extensive executive corporate experience in the medical device industry as CEO, President, COO of start-up and NYSE companies. Responsible for product development management and distribution, e.g. Technicon Corporation, Tarrytown, New York 1970 - 1979 Vice-President/General Manager (now Bayer Corporation), Narco Scientific, Pennsylvania former (NYSE) public company Executive Vice-President and General Manager, Colin Medical Instruments Corporation, San Antonio, Texas CEO, President, Director responsible for starting, building all North/South American operations. Japanese owned world-leader in non-invasive blood pressure and vital signs diagnostic and monitoring medical devices

Dr. Anil Rastogi: A senior executive with diverse leadership experience in several industries & in academic environment managing technology-driven businesses, start-up ventures & successfully completing IPO. Demonstrated success at commercialization of technology, bringing products from inception to market. Strong skills in establishing global strategic partners, strong organization development skills with bottom-line focus and a profit orientation. International experience in European and Pacific Rim markets. e.g. MEAD IMAGING, Dayton, Ohio 1987-1991 President, Cycolor Division 1989-1991, NOMOS Corporation, Sewickley, Pennsylvania leading supplier of radiation therapy treatment planning software and systems for cancer patients 1998-2002 President & Chief Executive Officer, OWENS-CORNING FIBERGLAS CORPORATION, Toledo, Ohio 1969-1987 Director, Corporate Diversification Portfolio 1983-1987

Sidney Braginsky: senior executive with diverse leadership experience in several industries was with Olympus Optical Ltd., Executive Vice-President and COO of the Olympus Scientific Products Group, a multi-national corporation 30 years in senior corporate and executive positions including serving from 1991 to 2001 as chief executive officer, and from 1999 to July 2001 as president and chief executive officer of Olympus America and executive vice-President and COO of the Olympus Scientific Products Group.

Mediscience Chief Executive Officer Peter Katevatis Esq. stated, "The three Board members and the recent employment of Mr. Benick CPA as Company CFO provide Mediscience significant and valuable depth of corporate and market experience to properly deploy specific applications of our IP Optical Biopsy platform technology." e.g.

  1. Ingestible Photonic Pill with our imbedded / IP Optical Biopsy platform technology, designed to distinguish cancerous, pre-cancerous, or benign tissues from normal tissue. (Equity partnered with both CUNY and Info tonics) and,

  2. Initiate FDA clinical trials for our CD Ratiometer(TM), a medical device utilizing Optical Biopsy designed to detect cervical cancer and/or physiological changes on a molecular level.

About Mediscience Technology Corp.

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

Investor Notice

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks and uncertainties including market conditions and FDA approval, which is required before the Camera Pill or the CD Ratiometer can be sold or licensed for use in the United States. This press release is intended to comply with Rule 135c promulgated under the Securities Act of 1933.

8-K filing dtd November 28, 2005 (directors)

8-K filing dtd November 8, 2005 (Chief Financial Officer)

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

www.cunyphotonics.com

medisciencetech.com

New England Journal of Medicine July-29-2004 (capsule endoscope technology)

CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20 (MTC/Info tonics)

SOURCE: Mediscience Technology Corp.

Mediscience Technology Corporation Michael Engelhard, 201-818-0050 [email protected] or Peter Katevatis Esq., 215-485-0362 [email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. NAMES FRANK BENICK, CPA CHIEF FINANCIAL OFFICER

CHERRY HILL, N.J., Nov 10, 2005 -- Mediscience Technology, Corp. (OTCBB:MDSC) announced today that Mr. Frank Benick, CPA has joined the company as its Chief Financial Officer effective November 15, 2005. Mr. Benick has extensive CFO experience in the management and supervision of public company accounting with specific expertise in all phases of accounting, and related SEC/Sarbanes matters. His consultant responsibilities will include advice/oversight of Mediscience management including but not limited to the filing of SEC Forms 1Q-Q, 10-K, weekly and monthly financial statements, installation of computer and accounting controls for cash, payroll, invoice payment, gross profit analysis and budgets.

The text of his employment agreement and CV is filed as Exhibit 99.1 to the Company's SEC 8-K filed November 10, 2005.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

Investor Notice

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/ IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. 8-K filing dated November 8, 2005.

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

www.cunyphotonics.com

medisciencetech.com

Mediscience SB-2 registration filing dated Dec. 23, 2004 effective Jan 12, 2005

New England Journal of Medicine July-29-2004 (capsule endoscope technology)

CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20 (MTC/Info tonics)

SOURCE: Mediscience Technology Corporation

Mediscience Technology Corporation Michael Engelhard, 201-818-0050 [email protected] or Peter Katevatis Esq., 215-485-0362 [email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. AND INFOTONICS TECHNOLOGY CENTER INC. REPORT "COMPACT PHOTONIC EXPLORER" (CPE), "PILL CAMERA" PROGRESS

CHERRY HILL, N.J., Oct 26, 2005--Infotonics Technology Center Inc. and Medi-photonics Development Company LLC, a subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, (MTC), (OTCBB- "MDSC"), announce that their joint development of the "Compact Photonic Explorer" (CPE), or "pill camera," for medical applications utilizing (MTC) optical biopsy IP, to advance to a production prototype, (manufacturable, meeting all "market-ready" product performance specs. on a best case scenario and an aggressive time-line) to be delivered in 12-18 months on an estimated R&D investment of $3 - 5M.

The parties announced their agreement to jointly develop the Compact Photonic Explorer (CPE), or pill camera, on September 8, 2004 The initial focus of the project --developing a (CPE) " that would detect cancer and monitor body functions". The goal - to create an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract. Such a non-invasive device would lead to reduced mortality and health care costs, and would significantly increase the number of people who could be screened for this type of cancer.

The proof-of-concept research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successful based upon an on-going four-year multidisciplinary/multi-institutional effort to develop miniature devices that use light to remotely monitor the health of various environments in collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University."

(Infotonics) is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems.

(MTC) Chairman/CEO Peter Katevatis stated "this joint effort between Medi-photonics and Infotonics is a synergistic and strategic fit leveraging the Center's unique nano-technology capabilities, resources and (MTC) optical biopsy IP. This project has enhanced (MTC) proprietary non-invasive imaging "optical biopsy" technology for molecular detection of cancer and physiological change and the Company's desire to commercialize its patented technology."

David R. Smith President & CEO (Infotonics) states "Capital investment would be required to establish the pilot production capability (e.g initial units for FDA clinicals) and the amount of capital funds would vary greatly with the production capacity required. From an R&D perspective we would proceed/participate in presentations etc together to seek competitive grant funding from NIH, and other available sources public and/or private. With our assistance and support Medi-Photonics LLC/Mediscience would at some early juncture contact/meet with the Empire State Development agency and Ontario County in New York State who have from project inception expressed significant New York State economic interest in the Rochester New York State area with significant financial incentives for the Compact Photonics Explorer (CPE) project should the project locate here. Infotonics is committed to support the appropriate path forward for Medi-Photonics LLC/Mediscience business success."

About the Infotonics Center

(Infotonics) is a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected IP noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

See Web sites:

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

www.cunyphotonics.com

medisciencetech.com

See Mediscience 8-K filing dated September 8, 2004

See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology)

CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page 20 (GIVEN IMAGING-Mediscience/Infotonics)

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/ company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; including but not limited to that expressed herein; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/ company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SOURCE: Mediscience Technology Corp.

Infotonics Technology Center, Inc David R. Smith [email protected] or Mediscience Technology Corp. Peter Katevatis, 215-485-0362 [email protected]

Top of page

MEDISCIENCE TECHNOLOGY ENGAGES INVESTMENT BANKERS

CHERRY HILL, N.J.--Mediscience Technology Corp. (OTCBB:MDSC) announced today that it has engaged the services of a United States investment banking firm as its exclusive placement agent for a proposed private placement on a best efforts basis of between $6 million and $10 million. The private placement is expected to commence during the fourth calendar quarter of 2005.

Mediscience Chief Executive Officer Peter Katevatis stated, "We intend to use the net proceeds of the proposed private placement to fund our ingestible optical biopsy capable 'Camera Pill' (designed to distinguish cancerous, pre-cancerous, or benign tissues from normal tissue) and initiate FDA clinical trials for our CD Ratiometer(TM), a medical device designed to detect cervical cancer on a molecular level and for general corporate purposes."

The proposed Private Placement will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirement.

About Mediscience Technology Corp.

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

Investor Notice

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks and uncertainties including market conditions and FDA approval, which is required before the Camera Pill or the CD Ratiometer can be sold or licensed for use in the United States. This press release is intended to comply with Rule 135c promulgated under the Securities Act of 1933.

Mediscience Technology Corp. Michael Engelhart, 201-925-5077 [email protected] or Peter Katevatis Esq., 215-485-0362 [email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES ITS SUCCESSFUL CLOSING ON AUGUST 16, 2005 OF A $1.525 MILLION DOLLAR PRIVATE PLACEMENT

CHERRY HILL, N.J., Aug 17, 2005 -- Mediscience Technology Corp. (MTC), (OTCBB- "MDSC"), a developer of imaging technology for molecular detection of cancer and physiological change, announced that on August 16, 2005 it privately closed its SEC Reg. "D" Private Placement with net cash infusion to the Company of $1.525 million dollars. And attached warrants totaling $3 million dollars exercisable at $1.00 per share.

Investment basis--SEC Reg. D Private placement: "The minimum subscription to August 15, 2005 this offerings closing, is $25,000 for each UNIT of Mediscience Common restricted per SEC Rule 144, each individual dollar investment to be no less than $25,000 for a minimum subscription of fourteen (14) UNITS ($350.000) to a maximum subscription of one hundred sixty (160) UNITS ($4,000,000). Each UNIT share of unregistered MTC common valued at fifty ($.50) cents per share with one warrant per share attached to purchase one additional share at one dollar ($1.00) a share of Mediscience common share restricted per SEC Rule 144, said warrant expiring by its terms on August 1, 2007. The Company reserved the right to accept or reject any subscription tendered, to August, 15, 2005 closing this offering in whole or in part on a smaller number of UNITS subscribed than the maximum of 160."

Chairman/CEO Peter Katevatis stated, "This funding will allow the company to move forward in our effort to commercialize our Optical Biopsy technology and immediately prepare and initiate clinical trials for Cervical cancer applications supportive to our August 18, 2005 meeting with the FDA."

SEE 8-K filing of registrants REG D filing dated August 16, 2005

Web Page: medisciencetech.com    www.cunyphotonics.com

8-K filing dated September 8, 2004

New England Journal of Medicine 7-29-04 (developing capsule endoscopy)

CITY GROUP/Smith Barney Analyst Report 10-01-2004 by Peter Bye, page 20 (MTC/INFOTONICS)

INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SOURCE: Mediscience Technology Corp.

Mediscience Technology Corp. Michael Engelhart, 201-818-0050 [email protected] or Peter Katevatis, 215-485-0362 [email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. SETS MEETING DATE WITH FDA TO REVIEW PRE-IDE SUBMISSION REGARDING CANCER DETECTION DEVICE; MEDISCIENCE TO MEET WITH FDA ON AUGUST 18, 2005 TO DISCUSS ITS CD-RATIOMETER DEV

CHERRY HILL, N.J. July 26, 2005 Mediscience Technology Corp. (OTC:MDSC) announced that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has been granted a date for a formal meeting with the FDA to discuss the possible commencement of a pivotal study by the FDA of its optical biopsy device, the CD-Ratiometer. The proposed indication for the use of the CD-Ratiometer is as a device that serves as an adjunct to diagnosis for cancer detection of the cervix and for other abnormalities.

The meeting is expected to expand upon the submission of the Pre-IDE document that was compiled by Schiff & Company, a firm specializing in international regulatory affairs, compliance and clinical research. Management expects to discuss aspects relating to clinical trials, fiber-optic probe details and the proposed indication of use of the CD-Ratiometer.

"The meeting with the FDA on August 18th will address the factors that can put Mediscience on the path to obtaining a submission for the IDE (Investigational Device Exemptions). We are eagerly looking forward to the in person opportunity to discuss the clinical protocol and determine the clearest path towards clinical efficacy for the CD-Ratiometer," said President and Chief Operating Officer, Michael Engelhart.

About Mediscience Technology:

Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

For additional information please visit: medisciencetech.com

Investor Notice:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Contact:

Contact Information: Mediscience Technology Michael Engelhart, President 201-925-5077 Peter Katevatis, CEO 215-485-0362 [email protected] or Media: Investor Relations Group Janet Vasquez / Mary Ann Mullady, 212-825-3210 or Investor Relations: Investor Relations Group Erik Lux/Adam Holdsworth/John Nesbett, 212-825-3210

Top of page

MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES PRE-IDE MEETING REQUEST FOR CD-RATIOMETER, A CANCER DETECTION DEVICE

CHERRY HILL, N.J. May 12, 2005 Mediscience Technology Corp. (OTC:MDSC) announces that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has requested a formal meeting with the FDA to discuss the CD-Ratiometer, an optical biopsy device as an adjunct to diagnosis for cancer detection of the cervix and other abnormalities. The submission of the Pre-IDE document was made by Schiff &Company, a firm specializing in International Regulatory Affairs, Compliance and Clinical Research.

"The meeting with the FDA has a purpose of determining any additional information required for submission of the IDE (Investigational Device Exemptions) and to determine the acceptability of the clinical protocol and establish the initial clinical efficacy of the CD-Ratiometer," said President and Chief Operating Officer, Michael Engelhart.

How Our Technology Works

Carcinogenesis is accompanied by molecular and structural changes in tissue. These changes affect the absorption, scattering and fluorescence properties of the tissue, and hence provide a method to spectroscopically (A spectroscope is a device that lets us find out what things are made of. It works by taking light and splitting it up into its component colors) distinguish malignant and pre-malignant tissue for normal or benign tissue.

About Mediscience Technology

Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

Investor Notice:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

CONTACT:

Mediscience Technology Michael Engelhart, 201-818-0050 [email protected]

Media: Investor Relations Group Janet Vasquez / Lynn Granito,
212-825-3210

Investor Relations: Investor Relations Group Erik Lux/Adam Holdsworth/John Nesbett, 212-825-3210

Top of page

MEDISCIENCE TECHNOLOGY CORP. DEVELOPING CANCER DETECTION INSTRUMENT FOR ANALYZING SURGICAL BREAST TISSUE SPECIMENS AT POINT-OF-CARE

Mediscience Technology, Corp. (OTCBB:MDSC) announced that it is in development of an adjunctive instrument called the Cancer Detection (CD) Map, to facilitate the acquisition of fluorescence images from surgical breast specimens (ex vivo) following lumpectomies and surgical procedures.

The instrument will be used to define the margins of tumors at the point-of-care, thus allowing the physician to obtain greater success in achieving clear margins in real time during cancer surgery without the use of extrinsic dyes, drugs or other invasive agents. The CD-Map is highly sensitive and can acquire images in less than one second. Zoom capability allows the CD-Map to acquire images over an area that can vary from sub-cm to several cm with a resolution better than 100 mm.

"We have performed prior studies on ex vivo tissue specimens and have demonstrated that fluorescence images acquired with the CD-Map can define regions of cancer, as well as identify other structures (i.e. veins, glands) inside tissue," said Michael Engelhart President and Chief Operating Officer. "We believe the CD-Map has the potential to greatly enhance patient outcomes at point-of-care through the delivery of clear margins confirmed through a pathology report," he added.

The CD-Map is a UV/visible fluorescence imaging system designed to gain image emission from native fluorophors in tissue. A tunable light source and movable filters permit the acquisition of images at multiple combinations of emission and excitation wavelengths. Intensity ratio maps are computer generated from the fluorescence images and either the intensity images or pseudo-color ratio images are displayed.

About Mediscience Technology

Mediscience Technology Corporation is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

Investor Notice

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SOURCE: Mediscience Technology

Mediscience Technology Michael Engelhart, 201-818-0050 [email protected] or Media: Investor Relations Group Janet Vasquez/ Lynn Granito, 212-825-3210 or Investor Relations: Investor Relations Group Erik Lux/Adam Holdsworth/John Nesbett, 212-825-3210

Top of page

MEDISCIENCE TECHNOLOGY CORP. NAMES DR. JULIAN KIM AS CONSULTANT FOR THE DEVELOPMENT OF THE JOINTLY PROPOSED MICRO-ENDOSCOPIC DEVICE UTILIZING MTC PROPRIETARY TECHNOLOGY FOR NATIVE FLUORESCENCE MOLECULAR MEASUREMENTS OF BREAST DUCTS

CHERRY HILL, N.J. Jan 27, 2005 Mediscience Technology, Corp. (OTCBB: MDSC) announced today that Dr. Julian Kim of the Cleveland Clinic has joined the company as a consultant. Dr. Kim is a Surgical Oncologist within the CC Dept. of General Surgery and a recognized expert in the study of applications of new technologies to assess breast ductal tissue. As a consultant to Mediscience, Dr. Kim will advise its management team on matters pertaining to: "guidance and expertise into the development of the jointly proposed micro-endoscopic device - Phase I project utilizing MTC proprietary technology for native fluorescence molecular measurements of breast ducts. Seminal product development work will occur at CUNY with government regulatory approval applications to follow.

Dr. Julian Kim has performed extensive studies on the use of micro-endoscopic instrumentation to perform visual assessment of the human breast ductal system. He has published several peer-reviewed manuscripts and is a leading authority on the advantages and current limitations of mammary ductoscopy. He has a special interest in methods of improving the identification of abnormal cells lining the breast ducts during the ductoscopy procedure in women with high-risk or known diagnosis of breast cancer. Quote-"It is a great privilege to collaborate with Mediscience management and Dr. Robert Alfano at CUNY to determine whether the use of auto-fluorescence during mammary ductoscopy can help to identify areas of abnormality which should undergo biopsy. The Mediscience proprietary auto-fluorescent technology has the potential to markedly improve the diagnostic sensitivity and specificity of the mammary ductoscopy procedure and result in measurable improvements in patient care".

Michael Engelhart Pres.COO "we continue to take advantage of our Intellectual Property in advancing the commercialization of screening and diagnostic cancer devices. We are delighted to have Dr Julian Kim of the Cleveland Clinic as a collaborator in our project --an individual who has demonstrated an expertise in detecting cancers of the breast in early stages.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

Investor Notice

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for the joint or independent development of various applications of its technology/ IP; the company's ability to enter into future agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory i.e. FDA clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Reference

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

www.cunyphotonics.com

medisciencetech.com

Mediscience SB-2 registration filing dated Dec. 23, 2004 effective Jan 12, 2005

New England Journal of Medicine July-29-2004 (capsule endoscopic technology)

CITIGROUP/Smith Barney Analyst Report 10-1-2004 see Pg. 20 (MTC/Infotonics)

CONTACT PERSONS:  Mediscience Technology Corp.
Michael Engelhart, 201-818-0050
[email protected]
or
Peter Katevatis Esq., 215-485-0362
[email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES COMPLETION OF DEVELOPMENT OF ITS OPTICAL BIOPSY CANCER DIAGNOSTIC RATIOMETER AND SUBMISSION TO THE FDA OF THE PRE-IDE BRIEFING MATERIALS

CHERRY HILL, N.J.--(BUSINESS WIRE)--Dec. 9, 2004-- Mediscience Technology Corp. (OTC:MDSC) announced today that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has completed development of its Optical Biopsy Cancer Diagnostic Ratiometer(TM) for the molecular screening and detection of cancer and physiological change. The Company also announced that it had submitted its Pre-IDE briefing materials to the United States Food and Drug Administration (FDA).

President and Chief Operating Officer Michael Engelhart stated "The timely completion of our Optical Biopsy Cancer Diagnostic Ratiometer should provide us with a clear path for our applications platform commercialization in the early screening, detecting and diagnosing of cancers of the cervix, mouth, esophagus and gastro intestinal tract." Engelhart added "We have submitted our initial Pre-IDE briefing materials for early screening and detection of abnormalities including cancer of the cervix with the FDA for marketing in the U.S."

Safe Harbor Statement: To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the availability of financing, the Company's ability to implement its long-range business plan for various applications of its technology, the Company's ability to enter into agreements with any necessary marketing and/or distribution partners, the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the Company' technology, and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

SEE: Web Page: medisciencetech.com Mediscience Form 8-K dated December 9, 2004

SOURCE: Mediscience Technology Corp.

CONTACT PERSONS:  Mediscience Technology Corp.
Michael Engelhart, 201-818-0050
[email protected]
or
Peter Katevatis Esq., 215-485-0362
[email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP./MEDI-PHOTONICS DEVELOPMENT COMPANY LLC AND INFOTONICS TECHNOLOGY CENTER ANNOUNCE THEIR DEFINITIVE COLLABORATIVE R&D EQUITY AGREEMENT

( BW)(NJ-MEDI-PHOTONICS)(MDSC) Mediscience Technology Corp./Medi-photonics Development Company LLC and Infotonics Technology Center Announce Their Definitive Collaborative R&D Equity Agreement.

CHERRY HILL, N.J.--(BUSINESS WIRE)--Nov. 10, 2004--Infotonics Technology, a Consortium of Corning, Inc.,Eastman Kodak Co. and Xerox Corp., to Develop the Mediscience (CPE) "Compact Photonic Explorer" Pill Camera.

Medi-photonics Development Company LLC, the NY subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. (MTC), (OTCBB:MDSC), a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, and Infotonics Technology Center announced the execution of their Collaborative Research and Development Agreement for the development of the Mediscience "Compact Photonic Explorer" (CPE), or "pill camera," to be commercialized by Mediscience for medical and non-medical applications. The initial project effort will utilize the Mediscience Intellectual Property to detect cancer and monitor physiological body functions throughout the digestive tract with a disposable swallowable pill.

The Parties will collaborate in the development of Mediscience commercially viable miniature devices making use of ultraviolet light to diagnose the health of living tissue; and remotely monitoring the health/status of various medical and non-medical environments, e.g., the detection of various types of cancer and monitoring of physiological body functions, the sensing of biological and chemical species such as bacteria and pollutants among others in the human body; and other non-medical applications.

The proof-of-concept funded research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successfully based upon an on-going four-year multidisciplinary/multi-institutional commitment to develop miniature devices that use light to remotely monitor the health of various environments in on-going collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University. Mediscience President Michael Engelhart stated, "Each Party's existing experience and knowledge base will be important in achieving the successful performance of the objectives of this Agreement, and each Party is expected to contribute from its experience and knowledge to maximize the commercial benefits from the Research. We have an agreement that aligns our interests and are confident in our mutual capabilities in implementing a process that leads to significant economic value. We are particularly pleased that Infotonics has accepted a one million share position in Mediscience for its $2 million contribution to the project with a 6 yr. warrant to acquire an additional million shares at an exercise of $3,00 per share. Mediscience Chairman/CEO Peter Katevatis Esq. stated, "This Agreement and managements desire to move forward to commercialization provides a timely opportunity to jointly explore our proprietary non-invasive imaging technology and develop the potential value and return to ourshareholders that we seek."

Les Fritzemeier, Infotonics' Director of Business Development and Government Programs, said such an agreement is "a milestone" for the Center, since the (CPE) stems from collaborative, Infotonics-funded research at eight universities over the past two years. "This is a prime example of the role the Infotonics Center can play in moving innovations into the marketplace to drive economic growth."

About the Infotonics Center

Infotonics Technology Center Inc. (Infotonics) is a consortium, not-for-profit Corporation, that operate New York State's Center of Excellence in Photonics and Microsystems. The Rochester NY State Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and Universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products, with major benefits to the region, including creation of jobs and attraction and development of new companies and investment revenue. The Infotonics Technology Center Inc. (Infotonics) operates New York State's Center of Excellence in Photonics and Microsystems. It is a not for profit consortium with founding participants Corning, Inc., Eastman Kodak Company, and Xerox Corporation.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, are engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, Pre-cancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

See Web sites: www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp
www.cunyphotonics.com
medisciencetech.com

See Mediscience 8-K filing dated September 8 , 2004

See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology)

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

CONTACT PERSONS:  Mediscience Technology Corp.
Michael Engelhart, 201-818-0050
[email protected]
or
Peter Katevatis Esq., 215-485-0362
[email protected]

Copyright Business Wire 2004

Top of page

INFOTONICS TECHNOLOGY CENTER AND MEDI-PHOTONICS DEVELOPMENT COMPANY LLC ANNOUNCED THEIR INTENT TO AGREE TO JOINTLY DEVELOP THE "COMPACT PHOTONIC EXPLORER". INFOTONICS IS A CONSORTIUM THAT INCLUDES CORNING, INC., EASTMAN KODAK COMPANY, AND XEROX CORPORATION, AND SEVERAL NEW YORK STATE UNIVERSITIES. INFOTONICS IS A WORLD-CLASS RESEARCH AND DEVELOPMENT FACILITY ESTABLISHED TO ENABLE THE RAPID COMMERCIALIZATION OF NEW HIGH TECH PRODUCTS.

CHERRY HILL, N.J.--(BUSINESS WIRE)--Sept. 8, 2004-- Infotonics Technology Center and Medi-photonics Development Company LLC, a subsidiary of Cherry Hill New Jersey-based Mediscience Technology Corp. (MTC), (OTCBB:MDSC), a developer of proprietary non-invasive imaging technology for molecular detection of cancer and physiological change, announced their intent to agree to jointly develop the "Compact Photonic Explorer" (CPE), or "pill camera," for medical and non-medical applications. The parties initial focus of the project is developing a (CPE) that would detect cancer and monitor body functions.

The proof-of-concept research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successful based upon an on-going four-year multidisciplinary/multi-institutional effort to develop miniature devices that use light to remotely monitor the health of various environments in collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University.

Infotonics Technology Center Inc. (Infotonics) is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems.

Mediscience President Michael Engelhart stated, "the first goal of a joint development initiative would be to create an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract. Such a non-invasive device would lead to reduced mortality and health care costs, and would significantly increase the number of people who could be screened for this type of cancer; further an agreement between Medi-photonics and Infotonics would be a synergistic and strategic fit leveraging the Center's unique nanotechnology capabilities and resources to provide our customers and partners with an exceptional state of the art competitive advantage."

Mediscience Chairman Peter Katevatis Esq. stated, "This project has and will continue to enhance Mediscience proprietary non-invasive imaging technology for molecular detection of cancer and physiological change and the Company's desire to move forward to commercialize its patented Optical Biopsy technology as it also prepares and initiates clinical trials for cervical cancer applications."

Les Fritzemeier, Infotonics' Director of Business Development and Government Programs, said such an agreement will be "a milestone" for the Center, since the (CPE) stems from collaborative, Infotonics-funded research at eight universities over the past two years. "This is a prime example of the role the Infotonics Center can play in moving innovations into the marketplace to drive economic growth."

Engelhart and Fritzemeier noted that medical applications for a photonic pill device would be just a starting point. Non-medical applications could involve sensing biological and chemical species, such as bacteria and pollutants, or for surveillance to determine the safety of compact structures and devices.

About the Infotonics Center

The Infotonics Technology Center Inc. (Infotonics) is a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

See Web sites: www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp
www.cunyphotonics.com
medisciencetech.com

See Mediscience 8-K filing dated September 8 , 2004

See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology)

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company's technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

CONTACT PERSONS:  Mediscience Technology Corp.
Michael Engelhart, 201-818-0050
[email protected]
or
Peter Katevatis Esq., 215-485-0362
[email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. PREVENTS UNAUTHORIZED LISTING OF COMPANY STOCK ON BERLIN-BREMEN STOCK EXCHANGE

CHERRY HILL, N.J., Aug 2, 2004 (BUSINESS WIRE) - Mediscience Technology Corp. (OTC:MDSC) announced today that it has successfully prevented the unauthorized listing of the Company's stock on the Berlin-Bremen Stock Exchange.

Recent public announcements by a substantial number of other U.S. publicly-traded companies indicate that they have been listed on the Berlin exchange without their permission. Financial media reports speculate these unauthorized listings may be part of an effort to avoid United States Securities and Exchange Commission restrictions against "naked short selling." Such practices may allow for market manipulation by selling non-existent shares of stock in an effort to force the price down.

Mediscience discovered the attempted listing of its Shares on the Berlin-Bremen Exchange without its approval, consent, or knowledge and immediately initiated contact with the Berlin-Bremen Stock Exchange demanding immediate de-listing of the Company's stock. Berlin-Bremen Stock Exchange legal counsel confirmed effective de-listing and zero trading activity on August 2, 2004. Mediscience believes this prompt action to de-list from the Berlin-Bremen Exchange, will maintain stability in its stock price and avert any potential market manipulation of its shares.

INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

Top of page

JUNE 15, 2004: NEW CD-ROM FROM OPTICAL SOCIETY OF AMERICA OFFERS COMPREHENSIVE COLLECTION OF PAPERS ON BIOMEDICAL OPTICAL BIOPSY

Dr. Robert R. Alfano, Director of City College’s Institute for Ultrafast Spectroscopy and Lasers, is the senior editor of a new CD-ROM entitled Biomedical Optical Biopsy that was released recently by the Optical Society of America (OSA). The CD-ROM is an important collection of over 300 classic articles from the earliest to the most recent on the subject of optical biopsy.

Optical biopsy involves the use of light and photonic technology to diagnose cancer without removing tissue from the body. It replaces invasive cancer detection techniques to determine its extent and assist in surgery and diagnostics.

Biomedical Optical Biopsy is an especially valuable resource for undergraduate and graduate students who are embarking on research involving optical biopsy, as well as for scientists, engineers and physicians in the field.

The CD-ROM is fully searchable by subject, keyword or author’s name. In addition to reprinted papers Biomedical Optical Biopsy contains lists of patents, books on optical biopsy, journals, resources for manuscript preparation and other useful information.

Among the numerous subject areas covered in Biomedical Optical Biopsy are the following: Fluorescence Biopsy, Raman Biopsy Techniques, Time-Resolved Techniques, Optical Coherence Reflectometry and Tomography, Confocal Microscopy, and Nonlinear Optical Imaging Techniques such as Second Harmonic Generation and Multiphoton Excitation.

Dr. Alfano is Distinguished Professor of Science and Engineering at CCNY. His co-editor is Dr. Barry Masters, a leading authority on multi-photon imaging.

"Biomedical Optical Biopsy offers a host of outstanding papers from the beginning of the field to the present by a wide-range of authors in a convenient, compact, easily searchable form," Dr. Alfano said.

The papers were selected on the basis of the innovative quality of the experimental or theoretical work, their educational value and their impact on the field.

"Papers were chosen because of their contributions in one or more of the following areas: pioneering work; sources of data; experimental method, and design technique," Dr. Alfano added.

The new CD-ROM will be especially useful to those who are interested in the field and want a guided tour through emerging areas of research.

To order the CD-ROM Biomedical Optical Biopsy from the Optical Society of America please go to www.osa.org/pubs/bookstore2

Top of page

MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES PROJECT AGREEMENT FOR DEVELOPMENT OF CANCER DETECTION AND DIAGNOSIS DEVICE WITH RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK

CHERRY HILL, N.J., (May 2, 2004) - MediPhotonics Development LLC a wholly owned New York Subsidiary of Mediscience Technology Corp (otc-mdsc)., announced that on May 1, 2004 it entered into a Project Agreement with The Research Foundation of City University of New York. Mediscience Technology of Cherry Hill, New Jersey, is a developer of imaging technology for molecular detection of cancer and physiological change.

President and COO Michael Engelhart stated "this Project Agreement provides the Company a clear path in its intent to commercialize the CD Ratiometer for detecting and diagnosing cancers of the cervix, mouth, esophagus and gastro intestinal tract and other potential applications that are compatible with current state of the art computer hardware and operating systems". Engelhart added, "We expect to have a completed device by November 30, 2004". RF-CUNY will complete production of the improved CD-Ratiometer instrument(s) by which Mediscience will seek approval by the United States Food and Drug Administration ("FDA") for marketing in the U.S. RFCUNY will apply its research and development to deliver an updated CD-Ratiometer and associated technology to be used in Mediscience Optical Biopsy, including the testing of the Mediscience CD-Ratiometer on ex vivo human tissue specimens. Under the specific terms of the Project agreement, Mediscience is granted an exclusive world-wide license, with the right to grant sublicenses, to make, use or sell all patented imaging product technology for molecular detection of cancer and physiological change Dr. Robert Alfano "The Project agreement and present world-wide Mediscience Patent positioning supports and extends the Mediscience core technology in Optical Biopsy, expanding, continuing and maintaining its leadership in the Optical Biopsy field".

INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SEE:
8-K filing dated May 2, 2004  
SEE:
Web Page: medisciencetech.com

CONTACT PERSONS:  Mediscience Technology Corp.
Michael Engelhart, 201-818-0050
[email protected]
or
Peter Katevatis Esq., 215-485-0362
[email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. NAMES ROBERT G. PINCO TO ADVISORY COUNCIL

CHERRY HILL, N.J., (April 14, 2004) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, announced today that Robert G. Pinco Esquire has joined the company's advisory council. Mr. Pinco is co-chairman of the BioMedical/FDA Practice and head of the firm's biotechnology group practice of Buchanan Ingersoll, a leading international law firm with specialization in the biotechnology sector. As a member of Mediscience's advisory council, Mr. Pinco will counsel its management team on matters pertaining to government regulatory approval for many of Mediscience's new products and applications in the U.S. and Europe.

Based in Washington, D.C., Mr. Pinco has more than 35 years of experience in the pharmaceutical sector. As a former director of the Over-the-Counter Drug Review of the FDA, he directed a massive review of more than 400,000 non prescription drugs, the largest, most complex project ever undertaken by that agency. He also held positions as White House Associate Counsel; Associate General Counsel, Special Action Office for Drug Abuse Prevention with the Drug Enforcement Administration (DEA); Assistant U.S. Attorney for the District of Columbia and as a pharmacist. Mr. Pinco is an Adjunct Associate Professor of Pharmacy Practices and Administrative Sciences at University of Maryland. He is also a member of the University of Connecticut, School of Pharmacy, Board of Advisors.

"Bob Pinco's professionalism and expertise in effectively navigating new products through the FDA and Buchanan Ingersoll's vast resources in the biotechnology sector, are invaluable to Mediscience as we prepare to introduce new medical screening and diagnostic devices to the U.S. marketplace," said Michael Engelhart President Chief Operating Officer of Mediscience.

About Mediscience Technology Corp.

Based in Cherry Hill, New Jersey, and New York City Mediscience Technology Corp., is engaged in the design, development, manufacturing and marketing of screening and diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy to distinguish between malignant and normal or benign tissue. Visit medisciencetech.com.

Forward-Looking Statements

The statements made in this press release discussing the potential of Mediscience's products and the potential for regulatory approval are forward looking statements within the meaning of the Private securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, Mediscience's raising sufficient funds to support its development, marketing efforts and corporate overhead, its ability to attract technical employees, the ability of Mediscience's management to grow its business with limited assistance and its ability to meet a variety of regulatory requirements. Mediscience has no duty and undertakes no obligation to update such statements.

CONTACT:  Mediscience Technology Corp.
Michael Engelhart, 201-818-0050
[email protected]
or
Peter Katevatis Esq., 215-485-0362
[email protected]

Top of page

MEDISCIENCE TECHNOLOGY CORP. (OTC-MDSC) ANNOUNCES THE SUCCESSFUL CLOSING OF A $1.5 MILLION DOLLARS PRIVATE PLACEMENT AS OF FEBRUARY 1, 2004

CHERRY HILL, N.J., (Feb 2, 2004) - Mediscience Technology Corp. (MTC), (OTCBB:MDSC) of Cherry Hill, New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced that on February 1, 2004 it privately closed an SEC Reg. “D” Private Placement for a net cash infusion to the Company of $1.5 Million dollars.

Investment basis: Mediscience Convertible Preferred Shares each priced at $25,000. No warrants or interest obligation attached, the Convertible Preferred shares may be converted into 100,000 shares of Mediscience common shares at the sole discretion of Mediscience subsequent to February 17, 2004. The company has agreed to file an SEC re-sale shelf registration S-3 within a period of 6 months or sooner after February 17, 2004.

Chairman/CEO Peter Katevatis stated “that this funding will allow the company to move positively forward in our intent and effort to commercialize our Optical Biopsy technology”.

INVESTOR NOTICE: Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company'technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.

SOURCE: Mediscience Technology Corp. Mediscience Technology Corp., Cherry Hill Michael Engelhart, [email protected] or Peter Katevatis Esq. [email protected]

Top of page

 
     Copyright © 2004 Mediscience Technology Corp. Contact Us